Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by West Virginia University
Information provided by (Responsible Party):
Dr. Abraham Kanate, West Virginia University
ClinicalTrials.gov Identifier:
First received: September 13, 2010
Last updated: December 8, 2014
Last verified: December 2014
This is a phase II study of allogeneic hematopoietic progenitor cell transplantation (HPCT) followed reduced toxicity conditioning with once daily intravenous Busulfex and fludarabine in patients with relapsed/chemotherapy refractory Hodgkin's and non-Hodgkin's lymphomas.

Condition Intervention Phase
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Drug: Busulfan
Drug: Fludarabine
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study

Resource links provided by NLM:

Further study details as provided by West Virginia University:

Primary Outcome Measures:
  • To assess 1-year progression free survival (PFS) of patients with chemotherapy refractory Hodgkin's and non-Hodgkin's lymphoma (NHL) undergoing reduced-toxicity conditioning (RTC) with once daily intravenous Busulfex and fludarabine. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To record 1 and 2 year overall survival (OS) following transplantation. [ Time Frame: At 1 year and 2 years ] [ Designated as safety issue: No ]
  • To record 2 year PFS. [ Time Frame: 12/31/13 ] [ Designated as safety issue: No ]
  • To assess nonrelapse mortality (NRM) following RTC transplantation at day +100 and 1-year. [ Time Frame: 12/31/13 ] [ Designated as safety issue: Yes ]
  • To assess relapse rate following transplantation at day +100 and 1-year. [ Time Frame: 12/31/13 ] [ Designated as safety issue: No ]
  • To assess disease response rate (RR) following transplantation at day +100 and at 1-year. [ Time Frame: 12/31/13 ] [ Designated as safety issue: No ]
  • To correlate OS, PFS, RR, NRM following HPCT with systemic busulfan exposure. [ Time Frame: 12/31/13 ] [ Designated as safety issue: Yes ]
  • To assess rates of acute and chronic graft versus host disease (GVHD). [ Time Frame: 12/31/13 ] [ Designated as safety issue: Yes ]
  • Time to successful neutrophil engraftment. [ Time Frame: 12/31/13 ] [ Designated as safety issue: Yes ]
  • Time to successful platelet engraftment. [ Time Frame: 12/31/13 ] [ Designated as safety issue: Yes ]
  • To assess rates of primary and secondary graft failure. [ Time Frame: 12/31/13 ] [ Designated as safety issue: Yes ]
  • To assess rates of primary and secondary graft rejection. [ Time Frame: 12/31/13 ] [ Designated as safety issue: Yes ]
  • To assess rates of pulmonary toxicity and venous occlusive disease (VOD) post transplantation, and assess correlation with Busulfex exposure levels. [ Time Frame: 12/31/13 ] [ Designated as safety issue: Yes ]
  • To assess lineage specific chimerism kinetics of donor cells following once daily IV Busulfex based RTC at days +30, +100, +180 and +365. [ Time Frame: 12/31/13 ] [ Designated as safety issue: No ]
  • To correlate chimerism kinetics following transplantation with Busulfex exposure levels. [ Time Frame: 12/31/13 ] [ Designated as safety issue: No ]
  • To determine immune reconstitution pattern at days +30, +100, +180, and +365. [ Time Frame: 12/31/13 ] [ Designated as safety issue: No ]
  • To evaluate biologic & genetic markers associated with the malignancy, GVHD and/or the treatment. [ Time Frame: 12/31/13 ] [ Designated as safety issue: No ]

Estimated Enrollment: 32
Study Start Date: September 2010
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Allogeneic hematopoietic progenitor cell transplant
Intravenous busulfex 130mg/m2 on days -6 to -3 before transplant
Drug: Busulfan
Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
Other Name: Busulfex
Drug: Fludarabine
Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
Other Names:
  • Fludarabine Monophosphate
  • Fludara

Detailed Description:

This study hopes to learn if giving intravenous (IV) busulfan with fludarabine before (as a conditioning regimen) allogeneic hematopoietic progenitor cell transplantation (HPC) is safe and helps patients with Non—Hodgkin´s Lymphoma (NHL) and Hodgkin´s Lymphoma (HL). An HPC transplant takes cells from a donor´s bone marrow and, after chemotherapy treatment with a conditioning regimen, infuses the donor´s cells into the patient´s body. Busulfan is a strong drug that suppresses the immune system and fludarabine is a chemotherapy (cancer fighting) drug. These drugs can stop the growth of cancer cells by breaking the Deoxyribonucleic acid (DNA) or genetic material which is necessary for the growth of both healthy and cancer cells. The use of IV busulfan with fludarabine as a conditioning regimen prior to HPC transplant is investigational (not approved by the Food and Drug Administration [FDA]).

Busulfan is only given once daily by IV in this study, which is also not approved by the FDA. Patients in this study will go through standard procedures for their disease like medical history, physical exam, blood tests, Multi Gated Acquisition Scan (MUGA) scan or echocardiogram, bone marrow aspirate or biopsy, and lung functions test. Patients will be asked to donate additional blood and bone marrow for this study and for potential future research on their blood related to this study. Because of the normal procedures for HPC transplants patients in this study will be hospitalized for 4 to 6 weeks or longer and will make frequent trips to the clinic to visit the study doctor for supervision for at least one year. Each patient will also have to have a central venous catheter inserted into a large vein above the heart. This is used to give the drugs and to take blood samples.

Participation in this study will last about two years. The study expects to enroll 32 patients and will open to at least two collaborating institutions in the future. Upon initial Institutional Review Board (IRB) approval enrollment will only occur at West Virginia University (WVU). The IRB will be notified before enrollment occurs at other institutions.


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients aged 18-70 years of age are eligible.
  2. Eligible histologies include:

    • B-cell, T-cell or NK-cell NHL refractory to frontline or salvage therapy defined as failure to achieve complete or partial remission according to standard criteria.
    • Diffuse large B-cell lymphoma relapsing within 12 months of finishing a rituximab containing first line chemotherapy regimen (regardless of response to salvage chemotherapy)or with evidence of c-myc. Primary refractory NHL (regardless of response to salvage chemotherapy).
    • Hodgkin lymphoma which is chemorefractory after at least two prior therapies.
    • Hodgkin and NHL in an untreated relapse.
    • Transformed NHL or chronic lymphocytic leukemia undergoing Richter's transformation (regardless of response to last chemotherapy). Patients with chemosensitive relapsed NHLs or Hodgkin lymphoma, but considered ineligible for curative therapy with autologous transplantation, because of (a) inability to collect stem cells, (b) prior autografting, (c) presence of myelodysplasia or (d) histology not considered curable with autografting in opinion of treating physician will be eligible.
  3. All patients must have at least one suitable HLA-matched sibling or volunteer unrelated donor available (according to institutional guidelines). HLA typing should be performed at least at serological level for HLA-A, -B, and -C and at allele level for HLA-DRB1. One antigen or allele level mismatch will be permitted between the donor and the recipient; however each donor/recipient pair must match at HLA-DRB1 at allele level.
  4. Patient must be able to provide informed consent.
  5. Left ventricular ejection fraction ≥ 40%. No uncontrolled arrhythmias or uncontrolled New York Heart Association class III-IV heart failure.
  6. Bilirubin, aspartate aminotransferase (AST), and Alanine transaminase (ALT) ≤ 3 x normal; and absence of hepatic cirrhosis.
  7. Adequate renal function as defined by a serum creatinine clearance of ≥ 40% of normal calculated by Cockcroft-Gault equation.
  8. DLCO (diffusion capacity; corrected for hemoglobin) or forced expiratory volume (FEV1) ≥ 50% of predicted.
  9. Karnofsky performance status ≥ 70.
  10. A negative pregnancy test will be required for all women of child bearing potential. Breast feeding is not permitted.

Exclusion Criteria:

  1. Patients eligible for potentially curative therapy with autologous transplantation.
  2. Patients with lymphoblastic lymphoma.
  3. Patients with positive human immunodeficiency virus (HIV) serology.
  4. Clinical evidence of uncontrolled bacterial, viral or fungal infection at the time of transplant conditioning.
  5. Prior allogeneic transplantation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01203020

Contact: Pam Bunner, MT, CCRC 304-598-4511 bunnerp@wvuhealthcare.com
Contact: Crystal Stevens, MT 304-598-4512 stevensc@wvuhealthcare.com

United States, West Virginia
West Virginia University Hospitals Mary Babb Randolph Cancer Center Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Pam Bunner, MT    304-598-4511    bunnerp@wvuhealthcare.com   
Contact: Crystal Street, MT    304-598-4512    streetc@wvuhealthcare.com   
Sub-Investigator: Michael Craig, MD         
Sub-Investigator: William Tse, MD         
Sub-Investigator: Aaron Cumpston, PharmD         
Sub-Investigator: Scot Remick, MD         
Sub-Investigator: William Petros, PharmD         
Sponsors and Collaborators
Dr. Abraham Kanate
Principal Investigator: Abraham Kanate, MD West Virginia University
  More Information

Responsible Party: Dr. Abraham Kanate, Assistant Professor, West Virginia University
ClinicalTrials.gov Identifier: NCT01203020     History of Changes
Other Study ID Numbers: WVU 11310 
Study First Received: September 13, 2010
Last Updated: December 8, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by West Virginia University:
allogeneic hematopoietic progenitor cell transplant
reduced-toxicity conditioning
reduced-intensity conditioning

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma, Non-Hodgkin
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Fludarabine phosphate
Alkylating Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 25, 2016